A sign hangs near the section for children's medicine at a Walgreens in New York City on Dec.19, 2022. (Photo by Fatih Aktas/Anadolu Agency via Getty Images)
Walgreens has ended limits it had imposed recently for online purchases of children’s over-the-counter fever reducing products.
The drugstore chain said improved supplies allowed it to lift its restriction of six products. The company had placed no limit on in-store purchases.
Last month both Walgreens and CVS Health restricted purchases of some over-the-counter children’s medicines citing supply issues. CVS Health put a two-product limit on all children’s pain relief products bought through its pharmacies or online.
A CVS Health spokeswoman said Tuesday that limits on some children's medicines remain in place. She did not offer a time frame for when it might end.
An unusually fast start to the annual U.S. flu season, plus a spike in other respiratory illnesses, created a surge in demand for fever relievers and other products people can buy without a prescription.
Shortages of medicines like Children’s Tylenol developed, varying around the country and sometimes even within communities.
Experts who track medicine shortages said in December that the problem could persist through the winter cold-and-flu season. But they noted that it should not last as long as other recent shortages of baby formula or prescription drugs.
Unpacking Jerome Powell’s surprise rate cut with Tematica Research CIO Chris Versace—what it signals, who wins, who loses, and what smart investors do now.
Ben & Jerry’s co-founder Jerry Greenfield is leaving the ice cream brand after 47 years. He says the freedom the company used to have to speak up on social issues has been stifled
The Trump administration has issued its first warnings to online services that offer unofficial versions of popular drugs like the blockbuster obesity treatment Wegovy.
Oracle soars as it cashes in on the AI boom, Plus: Starbucks shares continue to fall under its new CEO, and does anybody actually want a new iPhone Air?
Swedish buy now, pay later company Klarna is making its highly anticipated public debut on the New York Stock Exchange Wednesday, the latest in a run of high-profile initial public offerings this year. The offering priced at $40 Tuesday, above the forecasted range of $35 to $37 a share, valuing the company at more than $15 billion. The valuation easily makes Klarna one of the biggest IPOs so far in 2025, which has been one of the busier years for companies going public. Other popular IPOs so far this year include the design software company Figma and Circle Internet Group, which issues the USDC stablecoin..
